Cassava Sciences Inc

Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer’s disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier and Barry M. Sherman in May 1998 and is headquartered in Austin, TX.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Cassava Sciences advances Phase III trial with strong financial footing

Cassava Sciences is progressing well with Phase III trial milestones and financial stability, poised to announce critical trial results by year-end.
While facing challenges in data accuracy and increased expenses, the company's proactive approach and strategic planning present significant growth opportunities.
By focusing on innovation and market transformation, Cassava Sciences is positioned to redefine Alzheimer's disease diagnosis and treatment.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer’s disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier in May 1998 and is headquartered in Austin, TX.

Cassava Sciences stock crashed after a lawyer sought to stop studies of the biotech's experimental Alzheimer's treatment. That just makes SAVA stock a better opportunity.

Scrutiny Makes Cassava Sciences Stock a ‘Blood in the Street' Opportunity

SAN DIEGO, Aug. 30, 2021 /PRNewswire/ --  Robbins Geller Rudman & Dowd LLP announces that it filed a class action lawsuit charging Cassava Sciences, Inc. (NASDAQ: SAVA) and certain of its executives with violations of the Securities Exchange Act of 1934.  Purchasers of Cassava Sciences common stock between February 2, 2021 and August 24, 2021, inclusive (the "Class Period") have until October 26, 2021 to seek appointment as lead plaintiff in the Cassava Sciences class action lawsuit.

SAVA DEADLINE: Robbins Geller Rudman & Dowd LLP Files Class Action Suit Against Cassava Sciences, Inc. and Announces Opportunity for Investors with Substantial Losses to Lead Case

NEW YORK--(BUSINESS WIRE)--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Cassava Sciences, Inc. (“Cassava” or the “Company”) (NASDAQ: SAVA) in the United States District Court for the Western District of Texas on behalf of all persons and entities who purchased or otherwise acquired Cassava securities between February 2, 2021 and August 24, 2021, both dates inclusive (the “Class Period”). Invest

CASSAVA SCIENCES ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Cassava Sciences and Encourages Investors to Contact the Firm

Insider transactions have historically proven quite prescient for the trajectory of SAVA stock, so what do they imply today? The post Insiders Like Cassava Sciences, Which Might Be Good News appeared first on InvestorPlace.

Insiders Like Cassava Sciences, Which Might Be Good News

Cassava (SAVA) tanks yet again after Quanterix stated that it did not interpret the test results or prepare the data charts presented by the former.

Cassava (SAVA) Down as Quanterix Issues Statement on AD Study

Boston, Massachusetts--(Newsfile Corp. - August 30, 2021) - Berman Tabacco, a national law firm representing investors, is investigating potential securities law violations by Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA), a drug development company. About the Securities Class Action FiledOn August 27, 2021, a securities class action complaint was filed in the Western District of Texas on behalf of purchasers of Cassava common stock between February 2, 2021 and August 24,...

Berman Tabacco Announces Approaching Lead Plaintiff Deadline for Investors with Losses in Excess of $100,000 from Cassava Sciences, Inc.

Boston, Massachusetts--(Newsfile Corp. - August 30, 2021) - Block & Leviton announces that a class action lawsuit has been filed against Cassava Sciences, Inc. (NASDAQ: SAVA) for potential securities law violations. Investors who purchased shares and have lost money are encouraged to contact the firm to learn more about how they might recover those losses. For more details, visit https://www.blockleviton.com/cases/sava.What is this all about?On August 24, 2021, after market hours, Cassava Sciences stock dropped over...

LAWSUIT FILED: CASSAVA SCIENCES Sued for Securities Law Violations; Investors Should Contact Block & Leviton for More Information

The selling in Cassava Sciences, Inc. (NASDAQ:SAVA) stock is continuing unabated amid the controversy surrounding its Alzheimer's study data. The Cassava Analyst: Cantor Fitzgerald analyst Charles Duncan suspended the Neutral rating and $109 price target on Cassava shares.

Why This Cassava Sciences Analyst Is Dropping Coverage

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Cassava Sciences, Inc. (NASDAQ: SAVA) between February 2, 2021 and August 24, 2021, inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 26, 2021. SO WHAT: If you purchased Cassava Sciences securities during the

EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Cassava Sciences, Inc. Investors with Losses to Secure Counsel Before Important Deadline – SAVA

3 Reasons Cassava Sciences Stock Isn't Worth the Risk

Amid a regulatory tug-of-war over a proposed Alzheimer's disease treatment, SAVA stock has become a speculator's playground. The post Cassava Sciences Is on the Ropes, so Watch for a Dip-Buy Opportunity appeared first on InvestorPlace.

Cassava Sciences Is on the Ropes, so Watch for a Dip-Buy Opportunity

CorMedix

CarLotz

NEW YORK, NY / ACCESSWIRE / August 30, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court.

CLASS ACTION UPDATE for LOTZ, CRMD and SAVA: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

On behalf of a whistleblower or whistleblowers, the law firm of Labaton Sucharow has asked the FDA to halt Cassava Sciences' clinical trials on the basis of potential data manipulation. Perhaps the whistleblower's most serious charge is that Cassava Sciences turned to its own affiliated lab to overcome poor results reported by an independent lab.

Cassava Sciences And Alzheimer's Disease: Raising Doubts

BlueCity Holdings Limited

Stable Road Acquisition Corp

NEW YORK, NY / ACCESSWIRE / August 29, 2021 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment.

The Gross Law Firm Announces Class Actions on Behalf of Shareholders of SRAC, BLCT and SAVA

ATI Physical Therapy

NEW YORK, NY / ACCESSWIRE / August 29, 2021 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

SHAREHOLDER ALERT: CRMD ATIP SAVA: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

LOS ANGELES--(BUSINESS WIRE)---- $SAVA #CLASSACTION--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, continues its investigation on behalf of Cassava Sciences, Inc. (“Cassava” or the “Company”) (NASDAQ: SAVA) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your Cassava investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Its Investigation of Cassava Sciences, Inc. (SAVA) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)---- $SAVA #investors--The Law Offices of Frank R. Cruz Continues Investigation of Cassava Sciences, Inc. (SAVA) on Behalf of Investors

The Law Offices of Frank R. Cruz Continues Investigation of Cassava Sciences, Inc. (SAVA) on Behalf of Investors

San Francisco, California--(Newsfile Corp. - August 27, 2021) -  Hagens Berman urges Cassava Sciences, Inc. (NASDAQ: SAVA) investors with significant losses to submit your losses now.Visit: www.hbsslaw.com/investor-fraud/SAVA Contact An Attorney Now: SAVA@hbsslaw.com 844-916-0895Cassava Sciences, Inc. (SAVA) Investigation: The investigation focuses on whether Cassava misled investors about the integrity of preliminary analysis of a small clinical trial of the company's Alzheimer's drug, simufilam. On July 29, 2021 Cassava...

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Cassava Sciences, Inc. (SAVA) Investors to Contact Firm's Attorneys Now, Firm Investigating Possible Securities Law Violations

Quanterix Corp. took a swing at Cassava Sciences Inc. Friday, but then Cassava hit back, stressing that Quanterix was contracted to perform sample testing of the trial data that have been disputed.

Cassava Sciences punches back, after Qaunterix took a swing by saying it didn't interpret or prepare the disputed trial data

Boston, Massachusetts--(Newsfile Corp. - August 27, 2021) -  Berman Tabacco, a national law firm representing investors, is investigating potential securities law violations by Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA), a drug development company. If you sustained losses in excess of $100,000 from your transactions in Cassava securities during the Class Period and are interested in learning more about serving as Lead Plaintiff, please provide your information here: Shareholder Contact |...

SAVA: Berman Tabacco Alerts Investors with Losses of $100,000 from Investments in Cassava Sciences, Inc. of Deadline to Apply to Serve as Lead Plaintiff

BENSALEM, Pa.--(BUSINESS WIRE)---- $SAVA #CLASSACTION--Law Offices of Howard G. Smith continues its investigation on behalf of Cassava Sciences, Inc. (“Cassava” or the “Company”) (NASDAQ: SAVA) investors concerning the Company's possible violations of federal securities laws. On August 24, 2021, after the market closed, it was revealed that a Citizen Petition was filed with the United States Food and Drug Administration (“FDA”) requesting that the FDA halt two ongoing trials of Cassava's proprietary drug Simufilam. T

INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of Cassava Sciences, Inc. (SAVA) on Behalf of Investors

SAN DIEGO, Aug. 27, 2021 /PRNewswire/ --  Robbins Geller Rudman & Dowd LLP today announced that it filed a class action lawsuit charging Cassava Sciences, Inc. (NASDAQ: SAVA) and certain of its executives with violations of the Securities Exchange Act of 1934 and seeking to represent purchasers of Cassava Sciences common stock between February 2, 2021 and August 24, 2021, inclusive (the "Class Period").  The Cassava Sciences class action lawsuit was commenced on August 27, 2021 in the Western District of Texas and is captioned Brazeau v.

SAVA NOTICE: Robbins Geller Rudman & Dowd LLP Files Class Action Suit Against Cassava Sciences, Inc. and Announces Opportunity for Investors with Substantial Losses to Lead Case

The stock's been a wild ride for investors all year, and it's dropped more than 50% in two days. What's going on, and why am I bullish?

Why the Cassava Sciences Bears Are Wrong

AUSTIN, Texas, Aug. 27, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer's disease, today released a statement regarding plasma p-tau analysis from a previously disclosed randomized, controlled Phase 2b clinical study in patients with Alzheimer's disease. For this study, Cassava Sciences contracted with Quanterix Corp., a highly regarded, independent laboratory, to perform sample testing on blinded samples.

Cassava Sciences Releases Statement Regarding Plasma p-tau Analysis from a Previously Disclosed Phase 2b Clinical Study in Alzheimer's Patients

LOS ANGELES, Aug. 27, 2021 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ: SAVA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Ongoing Investigation Alert: The Schall Law Firm Announces it is Investigating Claims Against Cassava Sciences, Inc. and Encourages Investors with Losses to Contact the Firm

News for Cassava Sciences Inc Stock (SAVA)